Study of two experimental drugs for advanced small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests two experimental drugs, gocatamig and ifinatamab deruxtecan, for people with advanced small cell lung cancer. The goal is to see if this combination can help control the cancer, either as a first treatment or after initial standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have extensive-stage small cell lung cancer (cancer that has spread widely).
- If you've already been treated, it must have been only one type of treatment (platinum chemotherapy plus etoposide with an immunotherapy drug) and finished within the last 6 weeks, with no sign of cancer growth.
- You cannot have active cancer spread to the brain, spine, or the lining of the brain.
- You cannot have a history of lung conditions like scarring (interstitial lung disease) or severe lung problems.
- You must be willing to provide a tumor tissue sample either from a past biopsy or a new one.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two new drugs (gocatamig and ifinatamab deruxtecan) for people whose small cell lung cancer has spread or come back after standard chemotherapy. It aims to see if the combination works better than current options.
This study tests a new drug, ifinatamab deruxtecan, against the doctor's choice of standard treatments for people with extensive-stage small cell lung cancer that has returned after initial platinum-based chemotherapy. The goal is to see if the new drug works better and if it might be a new option for you.
This trial tests a new combination of drugs (I-DXd and atezolizumab, with or without carboplatin) as your first treatment for extensive stage small cell lung cancer. It has two groups: one for people who haven't started treatment yet, and another for those who've already had 4 cycles of a standard chemo-immunotherapy combination and are stable or better.
This trial tests a combination of a liposome-encased chemotherapy (irinotecan), a platinum drug, an immunotherapy, and a targeted therapy (anlotinib) as a maintenance treatment for extensive small cell lung cancer. The goal is to see if this approach helps keep the cancer from growing after initial successful treatment.
This trial tests a new drug called sacituzumab govitecan against the usual treatments for people with extensive-stage small cell lung cancer that has gotten worse after initial chemotherapy. It aims to see if the new drug helps patients live longer or have better outcomes.
This trial tests two immunotherapy drugs (sacituzumab govitecan with atezolizumab or durvalumab) as ongoing treatment to keep extensive-stage small cell lung cancer from progressing. It is for people who have already completed initial chemotherapy and immunotherapy without their cancer getting worse.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.